SEC Filings

10-K
ARRAY BIOPHARMA INC filed this Form 10-K on 08/11/2017
Entire Document
 

NOTE 2 – MARKETABLE SECURITIES

Marketable securities consisted of the following as of June 30, 2017 and 2016 (in thousands):
 
June 30, 2017
 
 
 
Gross
 
Gross
 
 
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
 
Cost
 
Gains
 
Losses
 
Value
Short-term available-for-sale securities:
 
 
 
 
 
 
 
U.S. treasury securities
$
108,174

 
$

 
$
(76
)
 
$
108,098

Mutual fund securities
292

 

 

 
292

 
108,466

 

 
(76
)
 
108,390

Long-term available-for-sale securities:
 
 
 
 
 
 
 
Mutual fund securities
732

 

 

 
732

 
732

 

 

 
732

Total
$
109,198

 
$

 
$
(76
)
 
$
109,122


 
June 30, 2016
 
 
 
Gross
 
Gross
 
 
 
Amortized
 
Unrealized
 
Unrealized
 
Fair
 
Cost
 
Gains
 
Losses
 
Value
Short-term available-for-sale securities:
 
 
 
 
 
 
 
U.S. treasury securities
$
53,113

 
$
8

 
$
(1
)
 
$
53,120

Mutual fund securities
224

 

 

 
224

 
53,337

 
8

 
(1
)
 
53,344

Long-term available-for-sale securities:
 
 
 
 
 
 
 
Mutual fund securities
596

 

 

 
596

 
596

 

 

 
596

Total
$
53,933

 
$
8

 
$
(1
)
 
$
53,940


The mutual fund securities shown in the above tables are securities held under the Array BioPharma Inc. Deferred Compensation Plan.

The fair value of marketable securities are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as Level 1, as described in Note 8 - Fair Value Measurements to our financial statements included elsewhere in this Annual Report on Form 10-K.

As of June 30, 2017, the amortized cost and estimated fair value of available-for-sale securities by contractual maturity were as follows (in thousands):
 
Amortized
 
Fair
 
Cost
 
Value
 
 
 
 
Due in one year or less
$
108,174

 
$
108,098

Total
$
108,174

 
$
108,098



F-22